Investigation of the use of a genetic-led approach for the management of multiple medications in the ageing population

Healthy aging pharmacogenomics & polypharmacy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN99830995

Enrollment

480

Registered

2021-09-28

Start date

2021-09-01

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients on three or more medications for cardiovascular disease, mental health, pain and gastroprotection Not Applicable

Interventions

Patients who are over 50 years of age taking three or more medicines will be identified. This study will focus on patients on medication for cardiovascular disease, mental health, pain and gastroprote

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Over 50 years of age 2. Taking three or more medications for cardiovascular health, pain (musculoskeletal), gastroprotection and mental health 3. Agree to follow up after pharmacogenomic analysis

Exclusion criteria

Exclusion criteria: 1. Do not have the capacity to consent to take part in the project 2. Suffering from terminal cancer or terminal disease 3. Pregnant 4. Suffering from severe mental illness 5. Under the age of 50 years 6. Are not able to understand English or translated material 7. Do not agree to follow up after pharmacogenomic analysis and in particular those patients who have actionable pharmacogenomic data

Design outcomes

Primary

Measure	Time frame
1. The number of patients with DNA variants indicating an actionable change in currently prescribed medication, measured using pharmacogenomic genotype data at the time of the medication review questionnaire 2. The number of recommended prescription changes per patient, measured based on pharmacogenomic genotype data at the time of the medication review questionnaire 3. Prescription changes (e.g. dose increase/decrease) recommended as a result of pharmacogenomic data at the time of the medication review questionnaire 4. The number of pharmacogenomic prescription changes actioned, recorded at the time of the medication review questionnaire 5. The reasons for acceptance or discounting of pharmacogenomic prescription changes, recorded at the time of the medication review questionnaire	—

Measure

Time frame

1. The number of patients with DNA variants indicating an actionable change in currently prescribed medication, measured using pharmacogenomic genotype data at the time of the medication review questionnaire 2. The number of recommended prescription changes per patient, measured based on pharmacogenomic genotype data at the time of the medication review questionnaire 3. Prescription changes (e.g. dose increase/decrease) recommended as a result of pharmacogenomic data at the time of the medication review questionnaire 4. The number of pharmacogenomic prescription changes actioned, recorded at the time of the medication review questionnaire 5. The reasons for acceptance or discounting of pharmacogenomic prescription changes, recorded at the time of the medication review questionnaire

—

Secondary

Measure	Time frame
1. The number of adverse drug reactions reported by patients pre- and post-receipt of pharmacogenomic data, measured using questionnaires pre-testing and at 1, 3, 6 and 12 months post-testing 2. The type of adverse drug reactions reported by patients pre- and post-receipt of pharmacogenomic data, measured using questionnaires pre-testing and at 1, 3, 6 and 12 months post-testing 3. The number of actionable pharmacogenomic variants which do not impact a patient's currently prescribed medications, measured using pharmacogenomic genotype data at the time of the medication review questionnaire 4. Anxiety measured using EQ-5D questionnaire at baseline, 1, 3, 6 and 12 months after consent 5. General practitioner and pharmacist confidence in the use of pharmacogenomic data, measured using a questionnaire at baseline, 1, 3 and 6 months 6. Service use review (e.g. hospital admissions, GP appointments) measured using GP records at baseline and 1 year	—

Measure

Time frame

1. The number of adverse drug reactions reported by patients pre- and post-receipt of pharmacogenomic data, measured using questionnaires pre-testing and at 1, 3, 6 and 12 months post-testing 2. The type of adverse drug reactions reported by patients pre- and post-receipt of pharmacogenomic data, measured using questionnaires pre-testing and at 1, 3, 6 and 12 months post-testing 3. The number of actionable pharmacogenomic variants which do not impact a patient's currently prescribed medications, measured using pharmacogenomic genotype data at the time of the medication review questionnaire 4. Anxiety measured using EQ-5D questionnaire at baseline, 1, 3, 6 and 12 months after consent 5. General practitioner and pharmacist confidence in the use of pharmacogenomic data, measured using a questionnaire at baseline, 1, 3 and 6 months 6. Service use review (e.g. hospital admissions, GP appointments) measured using GP records at baseline and 1 year

—

Countries

England, United Kingdom

Contacts

Public ContactSuzanne Drury

suzanne.drury@congenica.com+44 (0)1223499965

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026